Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT01497496 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: High Dose Methylprednisolone (HDMP)
DRUG: Ofatumumab
DRUG: Lenalidomide

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]